Positive 90-day GLP toxicology study results in non-rodents
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The study demonstrated a favorable safety profile, with no mortality or dose-limiting toxicities observed, supporting the drug's long-term dosing potential. These findings will aid in the regulatory preparation for future clinical activities under US FDA and Australian TGA guidelines.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- Approval received for NTI164 Phase 3 Clinical Study in ASD
- Quarterly Activities/Appendix 4C Cash Flow Report
- Binding Commitments Received for a $4 Million Placement
- Trading Halt
- Neurotech receives $4.73m R&D Tax Incentive Refund
Later from Neurotech International
- Appendix 4D & Half Year Report
- NTI initiates First Clinical Site for Phase 3 ASD Trial
- NTI secures Notices of Allowance for US patent applications
- US FDA clears IND for NTI164
- Neurotech secures $3.15 million R&D tax incentive loan
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International